BTAI - BioXcel Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BTAI is currently covered by 8 analysts with an average price target of $-53.13. This is a potential upside of $-55.56 (-2286.42%) from yesterday's end of day stock price of $2.43.

BioXcel Therapeutics's activity chart (see below) currently has 54 price targets and 81 ratings on display. The stock rating distribution of BTAI is 25% HOLD, 72.22% BUY and 2.78% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 94.64% with an average time for these price targets to be met of 370.6 days.

Highest price target for BTAI is $7, Lowest price target is $3, average price target is $3.31.

Most recent stock forecast was given by RAGHURAM SELVARAJU from HC WAINWRIGHT on 30-Jan-2025. First documented stock forecast 02-Apr-2018.

Currently out of the existing stock ratings of BTAI, 9 are a HOLD (25%), 26 are a BUY (72.22%), 1 are a SELL (2.78%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$3

$-0.37 (-10.98%)

$5

1 months 10 days ago
(30-Jan-2025)

25/25 (100%)

$-2.17 (-41.97%)

351

Sell

$7

$3.63 (107.72%)

2 months 5 days ago
(07-Jan-2025)

3/3 (100%)

$-0.54 (-7.16%)

280

Buy

$5

$1.63 (48.37%)

$7

2 months 6 days ago
(06-Jan-2025)

13/13 (100%)

$-4.17 (-45.47%)

437

Hold

$4

$0.63 (18.69%)

7 months ago
(12-Aug-2024)

3/3 (100%)

$-6.52 (-61.98%)

104

Hold

$3.5

$0.13 (3.86%)

7 months 3 days ago
(09-Aug-2024)

3/3 (100%)

$-8.2 (-70.09%)

254

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BTAI (BioXcel Therapeutics) average time for price targets to be met?

On average it took 370.6 days on average for the stock forecasts to be realized with a an average price target met ratio 94.64

Which analyst has the current highest performing score on BTAI (BioXcel Therapeutics) with a proven track record?

ROBYN KARNAUSKAS

Which analyst has the most public recommendations on BTAI (BioXcel Therapeutics)?

Robyn Karnauskas works at TRUIST and has 27 price targets and 15 ratings on BTAI

Which analyst is the currently most bullish on BTAI (BioXcel Therapeutics)?

Do Kim with highest potential upside - $93.85

Which analyst is the currently most reserved on BTAI (BioXcel Therapeutics)?

Raghuram Selvaraju with lowest potential downside - -$0.37

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?